Related Experiment Video
Updated: May 17, 2026
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
[Effect of XPA expression on the chemotherapy sensitivity of A549/DDP cells]
Qiang Zhang1, Jin-xiang Wu, Yu-ping Wei
1Department of Pulmonary Medicine, Shandong University, Jinan, China.
Aim:
To investigate the influence on platinum-based chemotherapy sensitivity by silencing xeroderma pigmentosum group A (XPA) gene expression in non-small cell lung cancer (NSCLC) drug resistance cell lines (A549/DDP).
Methods:
We detected the expression of XPA in lung normal and tumor tissues by immunohistochemistry, quantitative real-time PCR (qPCR) and Western blotting. We silenced XPA expression in A549/DDP cells by XPA-shRNA transfection, and detected the expression of XPA by qPCR and Western blotting. The cell sensitivity to cisplatin and the apoptosis of A549/DDP cells transfected with XPA-shRNA were determined by MTT assay.
Results:
The expression of XPA was higher in NSCLC tissues than that in normal lung tissues. Silencing XPA gene increased the apoptosis and sensitivity of A549/DDP cells to cisplatin.
Conclusion:
Silencing XPA gene can partly reverse the cisplatin resistance in human cisplatin-resistant NSCLC cell line A549/DDP.
Insights
Silencing the xeroderma pigmentosum group A (XPA) gene in non-small cell lung cancer cells enhances sensitivity to platinum-based chemotherapy. This approach may help overcome drug resistance in lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Non-small cell lung cancer (NSCLC) exhibits resistance to platinum-based chemotherapy.
- The xeroderma pigmentosum group A (XPA) gene is implicated in DNA repair mechanisms.
- Understanding XPA's role is crucial for developing strategies to overcome drug resistance.
Purpose:
- To investigate the effect of silencing the XPA gene on platinum-based chemotherapy sensitivity.
- To assess XPA gene expression in NSCLC tissues and drug-resistant cell lines.
- To evaluate the impact of XPA gene silencing on cisplatin resistance and apoptosis in A549/DDP cells.
Summary:
- XPA gene expression was found to be elevated in NSCLC tissues compared to normal lung tissues.
- Silencing XPA expression in the A549/DDP cisplatin-resistant NSCLC cell line was achieved via XPA-shRNA transfection.
- The study demonstrated that XPA gene silencing increased cisplatin-induced apoptosis and re-sensitized A549/DDP cells to cisplatin.
Impact:
- Silencing the XPA gene can partially reverse cisplatin resistance in NSCLC.
- This finding suggests a potential therapeutic strategy for improving chemotherapy efficacy in lung cancer patients.
- Targeting XPA may offer a novel approach to combat platinum-drug resistance in NSCLC.